| |
| | PTC Therapeutics — Genetic Disorders: PTC124 (Site not responding. Last check: 2007-11-05) |
 | | PTC124 is a novel, orally administered small-molecule compound that targets a particular genetic alteration known as a nonsense mutation. |
 | | Nonsense mutations are alterations in the DNA that, when transcribed into mRNA, introduce a premature translation termination codon. |
 | | It is estimated that, on average, 5-15% of patients with any of at least 1,800 distinct genetic disorders have a nonsense mutation as the underlying cause of the disease, including cystic fibrosis, Duchenne muscular dystrophy, spinal muscular atrophy, hemophilia, lysosomal storage disorders, retinitis pigmentosa, familial hypercholesterolemia and some forms of cancer. |
| www.ptcbio.com /3.1.1_generic_disorders.aspx (982 words) |
|